Ascendis Pharma A/S vs Digital Realty Trust, Inc. — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Digital Realty Trust, Inc. trades at $179.17 (market cap $66.75B). The key difference: Digital Realty Trust, Inc. is far larger — about 3.8× Ascendis Pharma A/S's market cap, and Digital Realty Trust, Inc. pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DLR | |
|---|---|---|
Market Cap | $17.74B | $66.75B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $203.91 |
52-Week Low | $163.32 | $147.93 |
Enterprise Value | $18.11B | $84.27B |
Dividend Yield | — | 2.7% |
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Digital Realty Trust (DLR) trades at $180.41, up 0.6% on the day, with a bearish technical signal despite strong analyst consensus. The stock shows robust fundamentals with revenue growth to $6.11B in 2025 and net income margin of 21.73%, though valuation ratios like P/E of 47.85 appear elevated. Recent news highlights a $7.8B acquisition of Blackstone's data center stake, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $218.77, implying 21% upside, supported by AI infrastructure expansion. Key risks include high debt levels, execution challenges from recent deals, and interest rate sensitivity. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near support at $178 warrants caution.
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →